A successful executive hire creates a natural temptation to stop questioning the appointment. The company grows. The executive delivers. The board gains confidence. The leadership team develops a rhythm. Years pass, and the executive becomes closely associated with the organization’s success. Then the business changes.
The company moves from development to commercialization. A platform becomes a product. A private company enters the public markets. An organization expands internationally. A founder steps back. A new financing strategy changes the pressure on the leadership team. The executive has not necessarily changed. The job has and that distinction matters.
One of the more difficult leadership questions for a growing life sciences company is not whether an executive is performing well today. It is whether the capabilities that made that executive successful remain the capabilities the company will need next.
Success can create its own blind spot
Boards and CEOs naturally want to retain leaders who have delivered results. Institutional knowledge matters, relationships matter, and replacing an experienced executive carries real cost and risk. But past success can also make an organization reluctant to reconsider leadership requirements.
The executive who helped a company navigate clinical development may have been exactly right for that stage. The company may now need someone who can build a commercial organization. A CFO who successfully managed a private company’s financing strategy may face a very different mandate after an IPO. A COO who excelled while the organization had 100 employees may need a different operating model when the company has several hundred employees across multiple locations.
None of these situations necessarily represents executive failure. They represent a change in context. The danger is waiting until the mismatch becomes visible in performance before acknowledging that the role itself has evolved.
The job description may have changed without anyone rewriting it
Executive roles rarely remain static in high-growth life sciences companies. The formal job description may still contain the same responsibilities it did five years earlier. The actual job can be completely different.
Consider a company moving from clinical-stage development toward commercialization. Five years earlier, the chief commercial officer might have been focused primarily on market assessment, launch planning, and building relationships with key stakeholders. Now the organization may need someone who can manage a commercial infrastructure, oversee a launch, build a larger team, work across market access, and make decisions based on increasingly complex revenue data. The title has not changed. The required leadership profile has. This is why succession planning should not simply ask, “Who could replace this person?” It should ask, “What will this role actually need to accomplish when the next person takes it?” That is a very different question.
Experience can become too specific
Experience is one of the most important factors in executive hiring, particularly in highly specialized sectors such as life sciences. But experience has a shelf life when the environment changes dramatically.
An executive can become extraordinarily knowledgeable about one business model, therapeutic area, regulatory environment, commercial structure, or stage of company development. That knowledge can be an enormous advantage until the company needs to operate differently. This creates a subtle challenge for boards.
The executive’s résumé becomes stronger every year because they accumulate more experience. At the same time, that experience can make their leadership profile increasingly optimized for the environment they already know. The question is not whether their experience is valuable. It is whether it remains relevant to the company’s next strategic problem.
The next phase may require a different kind of leader
Life sciences companies often cross several distinct organizational thresholds. Research becomes development. Development becomes commercialization. One product becomes a portfolio. A single market becomes multiple markets. A founder-led company becomes institutionally led. A private company becomes public. A handful of employees becomes a complex organization with multiple layers of management. Each transition changes the leadership equation.
The skills that matter most at one stage may become less important than other capabilities at the next. Early-stage organizations may place enormous value on adaptability, scientific credibility, resourcefulness, and the ability to operate without much infrastructure. Later-stage organizations may require greater experience with scale, systems, delegation, capital allocation, organizational design, and stakeholder complexity. The best leader for the next phase may therefore look surprisingly different from the person who led the previous phase successfully.
Loyalty should not replace strategic fit
Long tenure is often treated as an unqualified positive. It can be a tremendous asset. Long-serving executives understand the history behind decisions, know the organization’s people, and have relationships that would take years to recreate.
But tenure should not become a substitute for evaluating strategic fit. Boards can ask several straightforward questions:
- Has the company’s strategic direction changed materially since this executive was appointed?
- Has the role expanded or changed in ways that were never part of the original mandate?
- Which capabilities will become more important over the next three to five years?
- Does the current executive have evidence of succeeding in those circumstances?
- What capabilities does the organization currently lack at the executive level?
- If we were hiring for this role today, knowing what we know now, would we define the profile the same way?
That final question can be particularly revealing. It separates appreciation for what an executive has accomplished from an objective assessment of what the organization needs next.
This is where succession planning becomes strategic
Succession planning is sometimes treated as a contingency exercise: identify who could step in if a senior executive leaves unexpectedly. That is important, but it is only one part of the equation. Strategic succession planning asks whether the leadership architecture itself still matches the business. That requires looking beyond individual performance.
The board should understand which capabilities are critical to the next stage of the business, where those capabilities currently reside, and where meaningful gaps exist. It also means distinguishing between a development opportunity and a fundamental mismatch.
An executive may be capable of developing into the leader the company needs. In another situation, the gap may be too substantial or the transition too time-sensitive to close through development alone. Those are different decisions, and they require different responses.
The conversation should happen before there is a problem
One of the hardest moments for a board is realizing that a highly respected executive may no longer be the right fit for the organization’s future. By the time the issue becomes obvious, options can be limited.
The executive may already be struggling with the expanded mandate. Other members of the leadership team may have adapted around the gap. Investors may be asking questions. A critical milestone may be approaching. At that point, succession becomes reactive.
The better time to examine the question is while the executive is still performing well. That makes the conversation less personal and more strategic. It is possible to recognize an executive’s contribution, protect the organization’s institutional knowledge, and still ask whether the next phase requires a different leadership profile. In fact, doing so may be one of the clearest signs that a board is thinking beyond the current operating cycle.
Sometimes the best succession plan is not a replacement
Reassessing an executive does not automatically mean replacing them. The review may reveal that the current leader has the right capabilities and simply needs additional support around them. The company might add a complementary executive, restructure responsibilities, strengthen the leadership team, or give the existing executive access to expertise that was previously unnecessary.
In other cases, the analysis may show that the role itself has become too broad and needs to be redesigned. And sometimes it will point toward a different executive profile altogether. The value of the exercise is not the predetermined answer. It is creating enough clarity to make the decision deliberately rather than waiting for circumstances to make it for you.
The most important question is not “Is this executive still good?”
That question is almost too easy. A better question is: “Good for what comes next?” A leader can have an excellent track record, deep organizational knowledge, strong relationships, and years of successful performance behind them. Those things should be taken seriously. But leadership is always contextual.
The company that needed one kind of executive five years ago may need another today. The company it intends to become may need something different again. For boards and CEOs, recognizing that distinction early creates more options, not fewer. It allows leadership requirements to be designed around the future rather than inherited from the past. And in a sector where the distance between scientific progress and commercial reality can change quickly, that may be one of the most important succession conversations a leadership team can have.
We at GeneCoda® work with life sciences companies to assess executive leadership requirements against the business challenges ahead, not simply the requirements of the role as it exists today. If your organization is entering a new stage of growth and you are reassessing the leadership capabilities required to get there, contact us.
